DBD Bentué-Ferrer

D Bentué-Ferrer

*This is an algorithmically generated author record based on publicly available information.

D Bentué-Ferrer has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vigabatrin

    by D. Bentué-Ferrer, O. Tribut, J.-C. Alvarez, M.-J. Royer-Morrot

  • Tiagabine

    by D. Bentué-Ferrer, O. Tribut, J.-C. Alvarez, M.-J. Royer-Morrot

  • Lamotrigine

    by D. Bentué-Ferrer, O. Tribut, J.-C. Alvarez, M.-J. Royer-Morrot

  • Gabapentine

    by D. Bentué-Ferrer, O. Tribut, J.-C. Alvarez, M.-J. Royer-Morrot

    • 1 October 2006
      • p. S67-8

    [Advantages of different dosages of active metabolites in the follow-up of azathioprine treatment for Crohn disease].

    by B Cagnard, D Tosoni-Verlingue, O Tribut, C Moizard, L Bridoux-Henno, N Delaperriere, D Bentue-Ferrer, A Dabadie

  • Felbamate

    by D. Bentué-Ferrer, O. Tribut, J.-C. Alvarez, M.-J. Royer-Morrot

  • Effects of nicardipine and clonidine on cognitive functions and electroencephalography in hypertensive patients

    by T. Denolle, P. Sassano, H. Allain, D. Bentue-Ferrer, S. Breton, I. Cimarosti, B. Ouatara, M. Merienne, J.-M. Gandon

    The aim of this study was to investigate the cognitive and electroencephalography (EEG) short-term effects of a calcium antagonist, nicardipine, compared to placebo and clonidine (which, having known sedative effects, acted as a negative control) for 15 days in elderly hypertensive patients with memory complaints. Nicardipine and clonidine were compared with placebo in a double-blind, randomized, three-way cross-over controlled study after a 2-week placebo run-in period. This was a phase II clinical study carried out on out-patients in a single research centre. Fifteen elderly (63 +/- 10 years) hypertensive patients, without dementia but with memory complaints, were included. Psychomotor performance and cognition were assessed using both an extensive battery of validated psychometric tests (which evaluated attention and vigilance, body sway and memory) and an EEG profile. Cardiovascular parameters measured were blood pressure and heart rate. No detrimental effects of nicardipine were found on attention, vigilance, body sway or memory. Nicardipine produced a significant increase in alpha EEG energies, which may indicate possible alerting effects. In contrast, clonidine induced well-known deleterious sedative effects in psychometric tests and in EEG analysis (decrease in alpha and increase in delta and theta waves). The two drugs produced equivalent decreases in blood pressure at steady state. In conclusion, clonidine induced well-known sedative effects, while nicardipine did not impair central nervous system activity and may have had some short-term alerting effects in elderly hypertensive patients with memory complaints. This study supports the hypothesis of a dissociation between blood pressure and direct drug effects on the central nervous system.


    • 9 November 2002
      • Vol. 57  (4) , 379-84

    [Drug distribution systems in hospitals].

    by H Allain, E Polard, F Le Duff, L Flet, D Bentué-Ferrer

    Any drug generally made and marketed by drug companies must respect the quality standards conferred by New Drug Approval regarding both safety and efficacy. Once prescribed by a doctor, inside a hospital, the drug, or more precisely the decision of its prescription will follow a complex circuit, involving numerous intermediates (human and technical) leading to drug dispensation and follow-up. Regulatory guidelines and rules harmonise and standardise this drug pathway in hospitals. Any weakness in this distribution system will be the source of nosocomial drug iatrogeny. The present review aims at describing the different steps and stages from the prescription to an individual patient to drug administration and follow-up. The evaluation of this system will be mentioned in the perspective of optimisation. The computerised system is essential allowing tracking of a drug, and providing help for decision-making (by confrontation with data bases) and a research tool (i.e, pharmacoepidemiology). Different experiences of assessment of the performance of such a drug distribution system inside hospitals will be presented, trying to check the quality reference: the right drug, the right patient, the right moment, in good conditions. The challenge is to optimise and secure all steps of the process. This goal needs assessment and quality control of the different phases, opening the discussion between hospital policy and regulatory and technical considerations.

    • 30 March 2002
      • Vol. 31  (12) , 562-4

    [Effect of almitrine/raubasine on cerebral metabolism in the elderly].

    by H Allain, D Bentué-Ferrer

    Recent neurobiological data has led to renewed interest in oxygen (O2). The discovery of neuroglobin, protein varyingly present in the brain, has been enhanced by the elucidation of the mechanisms through which oxygen intervenes in neuronal metabolism. Almitrine/raubasine activates the metabolism of hypoxic/ischemic neurones by increasing O2 bioavailability. This mechanism supports the effects on behaviour obtained in various animal models and the benefits observed during clinical trials in elderly patients presenting with cognitive defects.

    • 1 January 2002
      • Vol. 158, S35-40

    [Mild Cognitive Impairment: potential therapeutics].

    by H Allain, D Bentue-Ferrer, S Belliard, J-M Reymann, M Djemaï, M Merienne

    Mild Cognitive Impairment (MCI) is an emerging concept used to describe memory decline and probably attention disturbances in otherwise intellectually intact individuals. MCI may be considered in 12 to 15 p. 100 of the cases as announcing an Alzheimer's Disease (AD). Although still speculative, the debate concerning the drugs susceptible to normalize symptoms of MCI or to stop conversion to AD must be raised. For that purpose, several long term clinical trials are running (antioxidants, nootropics, anticholinesterasics.) and new molecules in the pipe-line should be assessed in patients with the diagnosis of MCI.